Neoadjuvant PD-1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung.

Abstract

BACKGROUND:

A single-agent of anti programmed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) therapy has been explored for resectable lung cancer before surgery. However, the effectiveness and safety of neoadjuvant programmed cell death 1 (PD-1) blockade combined with chemotherapy have not been published.

METHODS:

Twenty-one consecutive patients with potentially resectable squamous cell carcinoma of the lung who received neoadjuvant therapy followed by surgery in Beijing Cancer Hospital were included in this study. Eight patients received two cycles of neoadjuvant platinum-based doublet chemotherapy combined with anti-programmed cell death 1 (anti-PD-1) therapy, while 13 patients received two cycles of neoadjuvant platinum-based doublet chemotherapy only. Chest computed tomography was repeated before neoadjuvant treatment and surgery. Adverse events were monitored. The major pathological response (MPR) rate was determined after surgery. Selected specimens were sent for immunohistochemical and multiplex immunofluorescence analyses, and T-cell receptor DNA sequencing.

RESULTS:

Compared with neoadjuvant chemotherapy alone, the combination of PD-1 blockade and chemotherapy increased the pathological complete response rate (37.5% vs. 7.69%) and MPR rate (50% vs. 38.46%). The pathological and radiological evaluations are not consistent. No unknown adverse effects were reported for all the patients. More tumor infiltrating lymphocytes were observed in patients who received PD-1 blockade. No unknown pathological features associated with PD-1 blockade were found. Immune suppression in the peritumoral spaces around the residual tumor cells was observed. The amino acid sequences of the T-cell receptors are not significantly shared among the patients.

CONCLUSIONS:

The combination of neoadjuvant chemotherapy and PD-1 blockade is safe and feasible, and might indicate an increased MPR and pathological complete response rate. More investigations are needed for the best combination of the neoadjuvant therapy.

• Authors: Yuan Feng, Wei Sun, Jie Zhang, Yang Wang, Jinfeng Chen, Xinying Liu, Liang Wang, Shaolei Li, Chao Lv, Fangliang Lu, Jianzhi Zhang, Yang Hong, Shanshan Xiao, Tao Wang, Raymond Jiao, Ziping Wang, Liping Qi, Nan Li, Yue Yang, Dongmei Lin, Jian Fang
• Journal: Thoracic cancer (Thorac Cancer) Vol. 13 Issue 3 Pg. 442-452 (02 2022) ISSN: 1759-7714 [Electronic] Singapore
• PMID: 34913597 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

Chemical References

• B7-H1 Antigen
• Immune Checkpoint Inhibitors

Topics

• B7-H1 Antigen (metabolism)
• Carcinoma, Squamous Cell (drug therapy)
• Humans
• Immune Checkpoint Inhibitors
• Lung (pathology)
• Lung Neoplasms (pathology)
• Neoadjuvant Therapy (methods)